Dr. Margaret von Mehren, MD
Claim this profileFox Chase Cancer Center
Studies Sarcoma
Studies Soft Tissue Sarcoma
11 reported clinical trials
44 drugs studied
Area of expertise
1Sarcoma
Stage IV
Stage III
RB positive
2Soft Tissue Sarcoma
Stage III
Stage IV
RB positive
Affiliated Hospitals
Clinical Trials Margaret von Mehren, MD is currently running
DCC-3116 + Anticancer Therapies
for Advanced Cancers
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents.
Recruiting1 award Phase 1 & 2
Targeted Therapy
for Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Recruiting1 award Phase 29 criteria
More about Margaret von Mehren, MD
Clinical Trial Related3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Margaret von Mehren, MD has experience with
- Cyclophosphamide
- Doxorubicin
- Doxil
- Ribociclib
- Everolimus
- GSK3901961
Breakdown of trials Margaret von Mehren, MD has run
Sarcoma
Soft Tissue Sarcoma
Liposarcoma
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Margaret von Mehren, MD specialize in?
Margaret von Mehren, MD focuses on Sarcoma and Soft Tissue Sarcoma. In particular, much of their work with Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Margaret von Mehren, MD currently recruiting for clinical trials?
Yes, Margaret von Mehren, MD is currently recruiting for 2 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Margaret von Mehren, MD has studied deeply?
Yes, Margaret von Mehren, MD has studied treatments such as Cyclophosphamide, Doxorubicin, Doxil.
What is the best way to schedule an appointment with Margaret von Mehren, MD?
Apply for one of the trials that Margaret von Mehren, MD is conducting.
What is the office address of Margaret von Mehren, MD?
The office of Margaret von Mehren, MD is located at: Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 United States. This is the address for their practice at the Fox Chase Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.